KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Total Liabilities (2016 - 2025)

Abbott Laboratories' Total Liabilities history spans 17 years, with the latest figure at -$52.8 billion for Q4 2025.

  • For Q4 2025, Total Liabilities fell 257.46% year-over-year to -$52.8 billion; the TTM value through Dec 2025 reached -$52.8 billion, down 257.46%, while the annual FY2025 figure was -$52.8 billion, 257.46% down from the prior year.
  • Total Liabilities for Q4 2025 was -$52.8 billion at Abbott Laboratories, down from $32.9 billion in the prior quarter.
  • Across five years, Total Liabilities topped out at $89.1 billion in Q2 2023 and bottomed at -$52.8 billion in Q4 2025.
  • The 5-year median for Total Liabilities is $73.0 billion (2021), against an average of $50.3 billion.
  • The largest annual shift saw Total Liabilities tumbled 660.72% in 2021 before it skyrocketed 215.21% in 2023.
  • A 5-year view of Total Liabilities shows it stood at -$24.3 billion in 2021, then skyrocketed by 195.66% to $23.2 billion in 2022, then surged by 215.21% to $73.2 billion in 2023, then plummeted by 54.2% to $33.5 billion in 2024, then tumbled by 257.46% to -$52.8 billion in 2025.
  • Per Business Quant, the three most recent readings for ABT's Total Liabilities are -$52.8 billion (Q4 2025), $32.9 billion (Q3 2025), and -$264.0 million (Q2 2025).